(HealthDay News) – Persistent use of antihypertensive treatments is greater with the new generation of beta-blockers, compared to atenolol, according to a study published in Cardiovascular Therapeutics.

Yun Jung Choi, from Hanyang University in South Korea, and colleagues analyzed persistent use of antihypertensive medications among 9978 patients (≥18 years) with newly diagnosed hypertension in 2012. The participants were without hypertension-related complication and had initiated treatment with beta-blocker monotherapy.

The researchers found that the rate of treatment persistence was higher in the non-atenolol group (P<.0001), and time to treatment discontinuation was earlier in the atenolol group (P<.0001). Compared to atenolol, new generation beta-blockers demonstrated a lower risk of treatment discontinuation (hazard ratio [HR]: 0.91), with notable improvement seen with carvedilol and nebivolol (HRs: 0.74 and 0.79, respectively). Betaxolol showed a substantially greater hazard for discontinuation versus atenolol.

Continue Reading

“This study demonstrated meaningful improvement in treatment persistence with new generation beta-blockers compared to atenolol, with betaxolol as exception,” the authors write.

Related Articles


  1. Choi YJ, Ah YM, Kong J, et al. Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study. Cardiovasc Ther. 2016; doi: 10.1111/1755-5922.12197.